抗生素治疗与接受免疫检查点阻断的初治黑色素瘤患者生存结局的关联
这项多中心回顾性队列研究纳入2013年6月至2018年9月间接受一线抗PD-1免疫检查点阻断的初治晚期不可切除皮肤或黏膜黑色素瘤患者578例,分析抗生素暴露与无进展生存和总生存的关联。结果显示,免疫检查点阻断前60天内使用抗生素与更差的无进展生存(校正HR 1.75,95%CI 1.22-2.52)和总生存(校正HR 1.64,95%CI 1.04-2.58)相关,而免疫检查点阻断开始后使用抗生素对无进展生存(校正HR 1.19,95%CI 0.89-1.60)或总生存(校正HR 1.08,95%CI 0.75-1.57)无影响。
要点
- 免疫检查点阻断前60天内抗生素暴露与更差的无进展生存和总生存相关。
- 免疫检查点阻断开始后使用抗生素对无进展生存或总生存无影响。
- 研究为多中心回顾性队列,纳入578例初治黑色素瘤患者。
核心结论
- 免疫检查点阻断前60天内抗生素暴露似乎与接受一线抗PD-1治疗的黑色素瘤患者更差的无进展生存和总生存相关,而免疫检查点阻断开始后使用抗生素似乎不影响无进展生存或总生存。
研究设计与样本
- 多中心回顾性队列研究,纳入2013年6月至2018年9月间接受一线抗PD-1为基础免疫检查点阻断治疗的初治晚期不可切除皮肤或黏膜黑色素瘤患者。
主要发现
- 578例患者中,7%在免疫检查点阻断前60天内使用抗生素,19%在免疫检查点阻断开始后使用抗生素。
- 免疫检查点阻断前抗生素暴露与更差的无进展生存相关(校正HR 1.75,95%CI 1.22-2.52)。
- 免疫检查点阻断前抗生素暴露与更差的总生存相关(校正HR 1.64,95%CI 1.04-2.58)。
- 免疫检查点阻断开始后使用抗生素对无进展生存无影响(校正HR 1.19,95%CI 0.89-1.60)。
- 免疫检查点阻断开始后使用抗生素对总生存无影响(校正HR 1.08,95%CI 0.75-1.57)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The interaction of gut microbiome and immune system is being studied with increasing interest. Disturbing factors, such as antibiotics may impact the immune system via gut and interfere with tumor response to immune checkpoint blockade (ICB). METHODS: In this multicenter retrospective cohort study exclusively treatment-naïve patients with cutaneous or mucosal melanoma treated with first-line anti-PD-1 based ICB for advanced, non-resectable disease between 06/2013 and 09/2018 were included. Progression-free (PFS), and overall survival (OS) according to antibiotic exposure (within 60 days prior to ICB and after the start of ICB vs. no antibiotic exposure) were analyzed. To account for immortal time bias, data from patients with antibiotics during ICB were analyzed separately in the time periods before and after start of antibiotics. RESULTS: Among 578 patients with first-line anti-PD1 based ICB, 7% of patients received antibiotics within 60 days prior to ICB and 19% after starting ICB. Antibiotic exposure prior to ICB was associated with worse PFS (adjusted HR 1.75 [95% CI 1.22-2.52]) and OS (adjusted HR 1.64 [95% CI 1.04-2.58]) by multivariate analysis adjusting for potential confounders. The use of antibiotics after the start of ICB had no effect on either PFS (adjusted HR 1.19; 95% CI 0.89-1.60) or OS (adjusted HR 1.08; 95% CI 0.75-1.57). CONCLUSIONS: Antibiotic exposure within 60 days prior to ICB seems to be associated with worse PFS and OS in melanoma patients receiving first-line anti-PD1 based therapy, whereas antibiotics after the start of ICB do not appear to affect PFS or OS.
引用
- Chorti E, Kowall B, Hassel JC, et al. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade. Eur J Cancer. 2024. PMID: 38306840. doi:10.1016/j.ejca.2024.113536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。